| Title |
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
|
|---|---|
| Published in |
Blood and Lymphatic Cancer: Targets and Therapy, April 2012
|
| DOI | 10.2147/blctt.s18701 |
| Pubmed ID | |
| Authors |
Rajni Sinha, Loretta Nastoupil, Christopher R Flowers |
| Abstract |
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCL is a clinically, biologically, and pathologically heterogeneous entity with biologically distinct subtypes that have different expected treatment outcomes. The addition of rituximab to combination chemotherapy has improved outcomes for all patients with DLBCL and can produce cure for many individuals. Relapsed DLBCL is generally managed with salvage chemo-immunotherapy followed by high dose therapy and autologous stem cell transplantation which can cure additional patients. However, outcomes for patients who relapse early after upfront rituximab and chemotherapy have a poorer prognosis. Novel therapies and strategies are desperately needed for these patients and several emerging treatments hold promise for improving DLBCL treatment outcomes in the future. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 5% |
| Unknown | 20 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 24% |
| Professor > Associate Professor | 4 | 19% |
| Student > Ph. D. Student | 3 | 14% |
| Student > Master | 2 | 10% |
| Student > Postgraduate | 2 | 10% |
| Other | 2 | 10% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 48% |
| Biochemistry, Genetics and Molecular Biology | 2 | 10% |
| Business, Management and Accounting | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 3 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2020.
All research outputs
#4,456,581
of 25,748,735 outputs
Outputs from Blood and Lymphatic Cancer: Targets and Therapy
#1
of 1 outputs
Outputs of similar age
#27,855
of 173,732 outputs
Outputs of similar age from Blood and Lymphatic Cancer: Targets and Therapy
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,732 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them